This company has shut down. Vibliome is no longer operating — its last tracked round was a Series A in 2022.
Explore the Startup GraveyardVibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
Vibliome has raised $38.0M in total funding. The most recent round was Series A. The last funding was announced in February 2022.
Vibliome's investors include Deerfield.
Vibliome is headquartered in Bozeman, United States.
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
Vibliome is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vibliome — Funding & Investors." VCBacked, February 24, 2022, https://www.vcbacked.co/company/vibliome. Accessed August 14, 2026.
VCBacked. (2022). Vibliome — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vibliome
{{cite web |title=Vibliome — Funding & Investors |url=https://www.vcbacked.co/company/vibliome |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated